What is Roth Capital’s Forecast for Beyond Air Q3 Earnings?

Beyond Air, Inc. (NASDAQ:XAIR) – Stock analysts at Roth Capital raised their Q3 2025 earnings estimates for shares of Beyond Air in a research note issued on Tuesday, November 12th. Roth Capital analyst J. Wittes now expects that the company will earn ($0.23) per share for the quarter, up from their prior estimate of ($0.27). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Beyond Air’s current full-year earnings is ($0.92) per share. Roth Capital also issued estimates for Beyond Air’s Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.53) EPS.

Several other analysts have also recently issued reports on XAIR. Roth Mkm reissued a “buy” rating and set a $2.00 price objective on shares of Beyond Air in a research note on Friday, August 16th. Piper Sandler cut their price objective on Beyond Air from $3.50 to $1.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $3.67.

Beyond Air Trading Down 5.4 %

NASDAQ XAIR opened at $0.50 on Friday. Beyond Air has a 12 month low of $0.30 and a 12 month high of $2.36. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.76 and a quick ratio of 2.42. The company has a 50-day moving average of $0.41 and a 200-day moving average of $0.67. The company has a market cap of $23.67 million, a P/E ratio of -0.36 and a beta of -0.18.

Beyond Air (NASDAQ:XAIR) last released its earnings results on Monday, November 11th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. Beyond Air had a negative net margin of 2,369.17% and a negative return on equity of 227.29%. The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $1.19 million. During the same period in the previous year, the company earned ($0.51) EPS.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Soros Fund Management LLC acquired a new stake in Beyond Air during the 3rd quarter valued at $573,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Beyond Air during the second quarter worth about $47,000. Gendell Jeffrey L lifted its stake in shares of Beyond Air by 30.4% in the first quarter. Gendell Jeffrey L now owns 1,461,071 shares of the company’s stock worth $2,542,000 after acquiring an additional 340,774 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Beyond Air by 5.0% in the first quarter. Vanguard Group Inc. now owns 1,399,298 shares of the company’s stock worth $2,435,000 after acquiring an additional 66,224 shares in the last quarter. 31.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Beyond Air

In related news, CEO Steven A. Lisi purchased 1,476,626 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was purchased at an average price of $0.50 per share, for a total transaction of $738,313.00. Following the acquisition, the chief executive officer now directly owns 3,249,411 shares in the company, valued at $1,624,705.50. The trade was a 83.29 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 20.10% of the stock is owned by insiders.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.